| 000 | 05117naa a22005777i 4500 | ||
|---|---|---|---|
| 001 | UMUN-OA-20261005-PPE-060 | ||
| 003 | local | ||
| 005 | 20261005174856.0 | ||
| 006 | m o d | ||
| 007 | cr|||||||||||| | ||
| 008 | 261005s2020 xx o u000 0 eng d | ||
| 024 | 7 |
_a10.1186/s12916-020-01753-0 _2doi |
|
| 035 | _a(local)OpenAlex:W3094622981 | ||
| 040 |
_alocal _beng _clocal |
||
| 041 | 0 | _aeng | |
| 100 | 0 |
_aRuth P. Norris _eauthor. |
|
| 245 | 1 | 0 |
_aAre there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis / _cRuth P. Norris; Rosie Dew; Linda Sharp [and others]. |
| 264 | 1 |
_a[Place of publication not identified] : _bBioMed Central, _c2020. |
|
| 300 | _a1 online resource (1 article). | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 500 | _aPublication type: Review article. | ||
| 500 | _aLinked open-access copy: published version. | ||
| 506 | 0 |
_aOpen access; no subscription required for the linked open-access version. _fUnrestricted online access _2star |
|
| 520 | 3 | _aBACKGROUND: Novel biological and precision therapies and their associated predictive biomarker tests offer opportunities for increased tumor response, reduced adverse effects, and improved survival. This systematic review determined if there are socio-economic inequalities in utilization of predictive biomarker tests and/or biological and precision cancer therapies. METHODS: MEDLINE, Embase, Scopus, CINAHL, Web of Science, PubMed, and PsycINFO were searched for peer-reviewed studies, published in English between January 1998 and December 2019. Observational studies reporting utilization data for predictive biomarker tests and/or cancer biological and precision therapies by a measure of socio-economic status (SES) were eligible. Data was extracted from eligible studies. A modified ISPOR checklist for retrospective database studies was used to assess study quality. Meta-analyses were undertaken using a random-effects model, with sub-group analyses by cancer site and drug class. Unadjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed for each study. Pooled utilization ORs for low versus high socio-economic groups were calculated for test and therapy receipt. RESULTS: Among 10,722 citations screened, 62 papers (58 studies; 8 test utilization studies, 37 therapy utilization studies, 3 studies on testing and therapy, 10 studies without denominator populations or which only reported mean socio-economic status) met the inclusion criteria. Studies reported on 7 cancers, 5 predictive biomarkers tests, and 11 biological and precision therapies. Thirty-eight studies (including 1,036,125 patients) were eligible for inclusion in meta-analyses. Low socio-economic status was associated with modestly lower predictive biomarker test utilization (OR 0.86, 95% CI 0.71-1.05; 10 studies) and significantly lower biological and precision therapy utilization (OR 0.83, 95% CI 0.75-0.91; 30 studies). Associations with therapy utilization were stronger in lung cancer (OR 0.71, 95% CI 0.51-1.00; 6 studies), than breast cancer (OR 0.93, 95% CI 0.78-1.10; 8 studies). The mean study quality score was 6.9/10. CONCLUSIONS: These novel results indicate that there are socio-economic inequalities in predictive biomarker tests and biological and precision therapy utilization. This requires further investigation to prevent differences in outcomes due to inequalities in treatment with biological and precision therapies. | |
| 540 |
_aCreative Commons Attribution (licence family recorded by the source; version not supplied in metadata). _uhttps://openalex.org/W3094622981 |
||
| 546 | _aIn English. | ||
| 588 | 0 | _aDescription generated from OpenAlex bibliographic metadata retrieved on 5 October 2026; full text linked from the source. | |
| 590 | _aCourse allocation: B. Sc. Politics, Philosophy and Economics. | ||
| 650 | 4 | _asocioeconomic disparities | |
| 650 | 4 | _aprecision oncology | |
| 650 | 4 | _ahealth care utilization | |
| 650 | 4 | _ahealth disparities | |
| 650 | 4 | _alung cancer | |
| 650 | 4 | _abreast cancer | |
| 653 | _aB. Sc. Politics, Philosophy and Economics | ||
| 653 | _aUMUN open access collection | ||
| 653 | _aeconomic inequality | ||
| 655 | 4 | _aReview articles. | |
| 700 | 0 |
_aRosie Dew _eauthor. |
|
| 700 | 0 |
_aLinda Sharp _eauthor. |
|
| 700 | 0 |
_aAlastair Greystoke _eauthor. |
|
| 700 | 0 |
_aStephen Rice _eauthor. |
|
| 700 | 0 |
_aKristina Johnell _eauthor. |
|
| 700 | 0 |
_aAdam Todd _eauthor. |
|
| 773 | 0 |
_tBMC Medicine _gVol. 18, no. 1, (2020), pages/article 282 _x1741-7015 |
|
| 856 | 4 | 0 |
_uhttps://bmcmedicine.biomedcentral.com/track/pdf/10.1186/s12916-020-01753-0 _yRead open-access publication _zOpen access. Access and licence reported by the source; this host could not be independently checked by automation. _70 |
| 884 |
_aCourse selection and automated MARC21 enrichment from OpenAlex metadata. _g20261005 _khttps://openalex.org/W3094622981 _qlocal |
||
| 942 | _n0 | ||
| 999 |
_c1072 _d1072 |
||